Due to COVID-19, new study enrollment is being assessed on a case by case basis. If you have any questions please call our central phone number at 616-391-1230.
Narrow List by Age:
(Refer to Clinical Summary for age requirements)
Protocol | TAPUR |
---|---|
Cancer Type: | Multisite |
Fast Facts |
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Protocol | EAY131 - MATCH |
---|---|
Cancer Type: | Molecular |
Fast Facts |
Molecular Analysis for Therapy Choice (MATCH)
Protocol | EAY131 - MATCH Protocol A |
---|---|
Cancer Type: | Molecular |
Fast Facts |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol A: EAY131-A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
Protocol | EAY131 - MATCH Protocol C1 |
---|---|
Cancer Type: | Molecular |
Fast Facts |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol C1: EAY131-C1: Crizotinib in Patients with Tumors with MET Amplification
Protocol | EAY131 - MATCH Protocol C2 |
---|---|
Cancer Type: | Molecular |
Fast Facts |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol C2: EAY131-C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
Protocol | EAY131 - MATCH Protocol E |
---|---|
Cancer Type: | Molecular |
Fast Facts |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol E: EAY131-E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
Protocol | EAY131 - MATCH Protocol J |
---|---|
Cancer Type: | Molecular |
Fast Facts |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol J: EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ, and Non-Colorectal Cancers with HER2 Amplification
Protocol | EAY131 - MATCH Protocol K2 |
---|---|
Cancer Type: | Molecular |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol K2: EAY131-K2: Phase II Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Mutations or Fusions.
Protocol | EAY131 - MATCH Protocol L |
---|---|
Cancer Type: | Molecular |
Fast Facts |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol L: EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
Protocol | EAY131 - MATCH Protocol M |
---|---|
Cancer Type: | Molecular |
Fast Facts |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol M: EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
Protocol | EAY131 - MATCH Protocol T |
---|---|
Cancer Type: | Molecular |
Fast Facts |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol T: EAY131-T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
Protocol | EAY131 - MATCH Protocol V |
---|---|
Cancer Type: | Molecular |
Fast Facts |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol V: EAY131-V: Phase II Study of Sunitinib in Patients with Tumors with c-Kit Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
Protocol | EAY131 - MATCH Protocol Z1C |
---|---|
Cancer Type: | Molecular |
Fast Facts |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1C: EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification
Protocol | EAY131 - MATCH Protocol Z1E |
---|---|
Cancer Type: | Molecular |
Fast Facts |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1E: EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
Protocol | EAY131 - MATCH protocol Z1F |
---|---|
Cancer Type: | Molecular |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1F: EAY131-Z1F: Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations (PTEN Loss Allowed)
Protocol | EAY131 - MATCH Protocol Z1G |
---|---|
Cancer Type: | Molecular |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1G: EAY131-Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
Protocol | EAY131 - MATCH protocol Z1L |
---|---|
Cancer Type: | Molecular |
Fast Facts |
Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol Z1L: EAY131-Z1L: Phase II Study of BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations
Protocol | EAY131 - MATCH Protocol Z1H |
---|---|
Cancer Type: | Molecular |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1H: EAY131-Z1H: Phase II Study of Copanlisib in Patients with Tumors with Deleterious PTEN Sequencing Result and PTEN Expression by IHC
Protocol | SWOG S1609 DART |
---|---|
Cancer Type: | Rare Tumors |
Fast Facts |
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | ACCRU 2018-01 |
---|---|
Cancer Type: | Untreated Solid Tumors |
Fast Facts |
Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A221602 |
---|---|
Cancer Type: | Cancer Control - Nausea |
Fast Facts |
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A231601CD |
---|---|
Cancer Type: | CCDR |
Fast Facts |
Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of an Efficient Pre-Surgical Toolkit (OPTI-Surg)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | DCP-001 |
---|---|
Cancer Type: | Multisite - Screening |
Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG AGCT1531 |
---|---|
Cancer Type: | Germ Cell |
Fast Facts |
A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Age:
Protocol | COG APEC14B1 |
---|---|
Cancer Type: | All patients |
Fast Facts |
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Subjects must be ≤ 25 Years of Age at Time of Original Diagnosis, except for Patients who are being Screened Specifically for Eligibility onto a COG (or COG Participating NCTN) Therapeutic Study, for whom there is a Higher Upper Age Limit.
Protocol | COG ALTE03N1 |
---|---|
Cancer Type: | Multi-site Cancer Control |
Fast Facts |
Key Adverse Events After Childhood Cancer
Diagnosis of Primary Cancer at Age 21 or Younger, Irrespective of Current Age.
Protocol | COG ALTE05N1 |
---|---|
Cancer Type: | Multisite Long Term Follow-up |
Fast Facts |
Umbrella Long-Term Follow-Up Protocol
Only Available to Patients Already Enrolled on a COG Intervention Protocol.
Protocol | COG ALTE07C1 |
---|---|
Cancer Type: | Multi-Site Cancer Control |
Fast Facts |
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer
Protocol | COG APEC1621 – MATCH Protocol SC |
---|---|
Cancer Type: | Screening |
Fast Facts |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Protocol | COG APEC1621 - MATCH |
---|---|
Cancer Type: | Molecular |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master Version Control Protocol
Protocol | COG APEC1621 - MATCH Protocol A |
---|---|
Cancer Type: | Molecular |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of LOXO-101 (larotrectinib) in patients with tumors harboring actionable NTRK fusions.
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 - MATCH Protocol B |
---|---|
Cancer Type: | Molecular |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations.
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 - MATCH Protocol C |
---|---|
Cancer Type: | Molecular |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of tazemetostat for patients with tumors harboring alterations in EZH2 or members of the SWI/SNF complex
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 - MATCH Protocol D |
---|---|
Cancer Type: | Molecular |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of LY3023414 in Solid Tumors
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 - MATCH Protocol F |
---|---|
Cancer Type: | Molecular |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 – MATCH Protocol G |
---|---|
Cancer Type: | Molecular |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutations
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
Protocol | COG APEC1621 – MATCH Protocol H |
---|---|
Cancer Type: | Molecular |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genes
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 – MATCH Protocol I |
---|---|
Cancer Type: | Molecular |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 – MATCH Protocol J |
---|---|
Cancer Type: | Molecular |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II Subprotocol of BVD-523FB (ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations dated 11/26/2019
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 - MATCH Protocol K |
---|---|
Cancer Type: | Molecular |
APEC1621K - NCI-COG Pediatric Molecular Analysis for Therapy Choice MATCH - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 - MATCH Protocol M |
---|---|
Cancer Type: | Molecular |
APEC1621M: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Tipifarnib in patients with tumors harboring HRAS genomic alterations
Patients must be ≥ 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621N |
---|---|
Cancer Type: | Molecular |
APEC1621N: NCI-COG Pediatric Molecular Analysis for Therapy Choice (MATCH) – Phase 2 Subprotocol of LOXO-292 in Patients Harboring RET Gene Alterations
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG ARST1921 |
---|---|
Cancer Type: | Other |
Fast Facts |
COG-ARST1921: A Safety, Pharmacokinetic and Efficacy Study of a Gamma-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.